Synthesis of two labeled forms of proteasome inhibitor MLN273

被引：3
|
作者：
Plesescu, Mihaela [1 ]
Ll, Yuexian [1 ]
Prakash, Shimoga R. [1 ]
机构：
[1] Millennium Pharmaceut Inc, Dept Drug Metab & Pharmacokinet, Cambridge, MA 02139 USA
来源：
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 2007年 / 50卷 / 5-6期
关键词：
C-14]MLN273; morpholine-4-[C-14]Carbonyl chloride; D-8]MLN273; L-[D-8]naphthylalanine;
D O I：
10.1002/jlcr.1176
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：428 / 430
页数：3
相关论文
共 50 条
  • [1] Synthesis of four isotopically labeled forms of a proteasome inhibitor, bortezomib
    Li, Yuexian
    Plesescu, Iviihaela
    Sheehan, Patrick
    Daniels, J. Scott
    Prakash, Shimoga R.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2007, 50 (5-6): : 402 - 406
  • [2] The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites
    Lindenthal, C
    Weich, N
    Chia, YS
    Heussler, V
    Klinkert, MQ
    PARASITOLOGY, 2005, 131 : 37 - 44
  • [3] Cytotoxic activity of the proteasome inhibitor MLN-273 but not of bortezomib is inhibited by MDR1.
    Rumpold, H
    Wolf, AM
    Untergasser, G
    Gastl, G
    Gunsilius, E
    Wolf, D
    BLOOD, 2005, 106 (11) : 195B - 195B
  • [4] The proteasome inhibitor MLN-273 inhibits cell cycle progression in Plasmodium falciparum parasites
    Lindenthal, C
    Weich, N
    Klinkert, MQ
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 293 : 85 - 85
  • [5] Syntheses of C-13 and C-14-labeled versions of the investigational proteasome inhibitor MLN9708
    Plesescu, Mihaela
    Elliott, Eric L.
    Li, Yuexian
    Prakash, Shimoga R.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2013, 56 (9-10): : 464 - 470
  • [6] Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
    Kupperman, Erik
    Lee, Edmund C.
    Cao, Yueying
    Bannerman, Bret
    Fitzgerald, Michael
    Berger, Allison
    Yu, Jie
    Yang, Yu
    Hales, Paul
    Bruzzese, Frank
    Liu, Jane
    Blank, Jonathan
    Garcia, Khristofer
    Tsu, Christopher
    Dick, Larry
    Fleming, Paul
    Yu, Li
    Manfredi, Mark
    Rolfe, Mark
    Bolen, Joe
    CANCER RESEARCH, 2010, 70 (05) : 1970 - 1980
  • [7] An Investigational Proteasome Inhibitor MLN9708 (MLN2238) Induces Apoptosis In Human Multiple Myeloma Cells In Vitro
    Masood, Aisha
    Chitta, Kasyapa
    Miles, Kiersten M.
    Khan, Nazmul H.
    Adelaiye, Remi
    Akhtar, Drusilla
    Sher, Taimur
    Chanan-Khan, Asher A.
    BLOOD, 2010, 116 (21) : 1264 - 1265
  • [8] Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease
    Garcia-Gomez, Antonio
    Quwaider, Dalia
    Canavese, Miriam
    Ocio, Enrique M.
    Tian, Ze
    Blanco, Juan F.
    Berger, Allison J.
    Ortiz-de-Solorzano, Carlos
    Hernandez-Iglesias, Teresa
    Martens, Anton C. M.
    Groen, Richard W. J.
    Mateo-Urdiales, Joaquin
    Fraile, Susana
    Galarraga, Miguel
    Chauhan, Dharminder
    San Miguel, Jesus F.
    Raje, Noopur
    Garayoa, Mercedes
    CLINICAL CANCER RESEARCH, 2014, 20 (06) : 1542 - 1554
  • [9] Antitumor activity of the investigational proteasome inhibitor MLN9708 in preclinical models of NSCLC
    Chattopadhyay, Nibedita
    Bannerman, Bret
    Donelan, Jill
    Bano, Kristen
    Blakemore, Steve
    Yang, Yu
    Stringer, Brad
    Manfredi, Mark
    Berger, Allison
    CANCER RESEARCH, 2011, 71
  • [10] Preclinical evaluation of the proteasome inhibitor ixazomib (MLN2238) on nasopharyngeal cacinoma (NPC)
    Li, Ka Yee
    Lee, Victor Ho Fun
    Tsao, George Sai Wah
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
12345